Stories
Divi's Laboratories Shares Surge After EU Panel Backs Weight Loss Drug
C
CNBC TV18•19-10-2026, 10:20
Divi's Laboratories Shares Surge After EU Panel Backs Weight Loss Drug
- •Shares of Divi's Laboratories Ltd. gained following a positive opinion for the weight loss drug Orforglipron from Europe's CHMP.
- •Orforglipron, also known as Foundayo, is an oral weight loss drug developed by Eli Lilly.
- •Analysts expect Divi's Laboratories to act as the intermediate supplier for the drug, boosting market confidence.
- •The USFDA previously approved Foundayo for weight loss, and the drug generated strong global sales in the second quarter of 2026.
- •Divi's Laboratories reported a robust financial performance in the first quarter of the fiscal year, with net profit surging 65.6 percent.
Key Questions Answered
Divi's Laboratories shares rose after Eli Lilly's oral weight-loss drug Orforglipron received a positive opinion from Europe's CHMP, with analysts viewing Divi's as the likely intermediate supplier.
The US Food and Drug Administration approved the oral weight-loss drug Foundayo on April 1, 2026.
In the first quarter of the fiscal year, Divi's Laboratories reported a consolidated net profit increase of 65.6% to reach ₹902 crore, up from ₹545 crore the previous year.
